Rallybio Corp (RLYB) · Nov 4, 2026 · Acquisition

Rallybio merger vote clears, $83.6M cash payout set

Merger approved — $83.6M cash distribution, or $13.90 per share

Rallybio’s merger vote clears the path to Avenzo, with an exact $83.6 million cash distribution and closing expected November 6.

Rallybio is transitioning from its legacy biotech business into a public-company vehicle for Avenzo, a clinical-stage oncology company with a pipeline of targeted small molecules and antibody-drug conjugates; Avenzo investors and financing participants are expected to own the overwhelming majority of the combined company after closing. The transaction has cleared its main shareholder hurdle. Investors approved the share issuance that will create a change of control, the reverse-split authorization, the name change to Avenzo Therapeutics, and the increase in authorized shares. 〔0〕 〔1〕 〔2〕 〔3〕 This is mostly confirmation rather than a surprise: the merger and its expected fourth-quarter closing were already public, so the vote advances the plan but does not rewrite it.

ItemCurrentPrior reference
Cash distribution (Item 8.01)$83.6M$82.7M estimate
Per-share distribution (Item 8.01)$13.90$13.56 estimate
Shares approved for merger issuance (Item 5.07)4,506,703 for15,979 against

The exact cash return is modestly better than previously indicated. Rallybio finalized the special distribution at $83.6 million, or $13.90 per share, versus the earlier disclosed estimate of $82.7 million and $13.56 per share. That is a small positive detail, but it is not operating progress from the legacy business; it is the cash being returned as Rallybio hands control of the public company to Avenzo.

The remaining risk is execution, not shareholder approval. The company expects the merger to close on November 6, 2026, subject to remaining closing conditions, while the new Avenzo equity plans and the reconstituted board only become effective in connection with closing. 〔4〕 The approved 18% equity reserve and recurring 5% annual increase also establish a substantial future equity-compensation capacity for the combined oncology company.

Bottom line: This filing moves Rallybio from an announced reverse merger to an approved transaction with a defined cash payout and an imminent closing date. It is mildly better than expected because the distribution is above the prior estimate, but the core merger outcome was already largely known. ⟧

What to watch next

Merger closing, November 6, 2026

Original filing on SEC EDGAR

More Rallybio Corp news

Rallybio merger vote clears, $83.6M cash payout set | RLYB Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.